BMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n1719 (Published 14 July 2021)Cite this as: BMJ 2021;374:n1719https://www.bmj.com/content/374/bmj.n1719?int_source=trendmd&int_medium=cpc&int_campaign=usage-042019
Study compares risk of blood clotting problems after covid-19 infection and vaccination
The risk of blood clotting problems is much higher after covid-19 infection than after receiving a covid-19 vaccine, according to research from the University of Oxford.
The study, published in the British Medical Journal, looked at more than 29 million people aged 16 or older who had a first dose of the Oxford/AstraZeneca or Pfizer/BioNTech vaccine in England between December 2020 and April 2021. It focused on the risks of blood clots and thrombocytopenia, a condition involving low levels of platelets – cells that help the blood clot.
Their findings suggest the risk of thrombocytopenia in someone with the coronavirus is almost nine times higher than in someone who has had one dose of the Oxford jab. They estimated that in 10 million people vaccinated with this jab, there would be 107 additional cases of thrombocytopenia in the 28 days post-vaccination, compared with 934 in vaccinated people infected with the virus.
The analysis found an association between vaccination with the Pfizer jab and an increased risk of stroke, but the risk was more than 10 times greater after infection with the virus. There were an estimated 143 extra cases of ischaemic stroke per 10 million people within 28 days of the Pfizer vaccine, compared with 1699 cases within 28 days of a positive covid-19 test.
For cerebral venous sinus thrombosis, a type of blood clot in the brain, as well as other types of blood clot, the risks were also much higher after covid-19 than after either jab.
Read more: https://www.newscientist.com/article/2237475-covid-19-news-pupils-urged-to-take-tests-as-they-return-to-school/#ixzz75862JO6q
The Defense Department is working closely with the Federal Emergency Management Agency, the Department of Homeland Security, the Department of Health and Human Services and the State Department to provide support in dealing with the coronavirus pandemic.
DOD VACCINATION ADMINISTRATION TO DOD POPULATION
D COVID-19 CUMULATIVE TOTALS
CasesHospitalizedRecoveredDeathsMilitary 226,510 2,036 213,964 34
Civilian 60,049 1,696 50,573 274
Dependent 33,259 434 31,329 17
Contractor 21,237 578 19,009 94
Total 341,055 4,744 314,875 419
ArmyMarine CorpsNavyAir ForceNational GuardDOD Agencies79,156 26,061 43,921 38,218 37,793 1,361
DOD Vaccination Data
ArmyMarine CorpsNavyAir Force
Service Member TotalDOD Civilian
Partially Vaccinated 175,588E9 16,030E9 22,840E9 32,833E9 247,291E9 46,955E9
Fully Vaccinated 395,752E9 113,859E9 293,098E9 292,667E9 1,095,376E9 308,396E9
Notes Data updated 0500, August 25, 2021Government ResourcesCoronavirus.gov CDC.gov USA.gov MySymptoms.mil
RELEASE | Aug. 27, 2021DOD Awards $6.5 Million Contract to U.S. Cotton, LLC, to Increase Domestic Production Capacity of Polyester-Tipped Swabs
PUBLICATION | Aug. 25, 2021Memorandum for Mandatory Coronavirus Disease 2019 Vaccination of Department of Defense Service Members
PUBLICATION | Aug. 25, 2021COVID-19 Travel Restrictions Installation Status Update, August 25, 2021
TRANSCRIPT | Aug. 11, 2021Pentagon Press Secretary John F. Kirby Holds a Press Briefing
NEWS RELEASE| Aug. 23, 2021
DOD Awards $0.6 Million Contract to QIAGEN to Increase Domestic Production Capacity of COVID-19 Diagnostic Test Kits and Reagents
The Defense Department awarded a $0.6 million contract to QIAGEN Beverly, Inc. to expand manufacturing capacity of enzymatic reagents and reagent kits used in COVID-19 molecular diagnostic tests.
PUBLICATION | July 30, 2021
Transition to Health Condition Bravo on the Pentagon Reservation
PUBLICATION, RELEASE, MEMORANDUM,STATEMENT, TRANSCRIPT, NEWS RELEASE.
MEMORANDUM @ PUBLICATION. RELEASE @ ACTION, MEMORANDUM @ POLICY.
https://www.defense.gov/Explore/Spotlight/Coronavirus-DOD-Response/
No comments:
Post a Comment